Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)

PHASE4CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

May 31, 2013

Study Completion Date

September 30, 2013

Conditions
Secondary HyperparathyroidismChronic Kidney Disease
Interventions
DRUG

Paricalcitol

1 mcg daily, adjusted to achieve 40-60% PTH suppression

DRUG

Calcitriol

0.25 mcg daily, adjusted to achieve 40-60% PTH suppression

Trial Locations (4)

48202

Henry Ford Hospital, Detroit

60201

Northshore University Health System, Evanston

60611

Northwestern University, Chicago

63110

Washington University, St Louis

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Henry Ford Hospital

OTHER

collaborator

Northwestern University Feinberg School of Medicine

OTHER

collaborator

Endeavor Health

OTHER

collaborator

Abbott

INDUSTRY

lead

Washington University School of Medicine

OTHER